Milestones in Dosimetry for Nuclear Medicine Therapy

Overview

Journal Br J Radiol

Publisher Oxford University Press

Specialty Radiology

Date 2022 Apr 22

PMID 35451857

Authors

Jonathan Gear

Affiliations

Soon will be listed here.

Abstract

Nuclear Medicine therapy has reached a critical juncture with an unprecedented number of patients being treated and an extensive list of new radiopharmaceuticals under development. Since the early applications of these treatments dosimetry has played a vital role in their development, in both aiding optimisation and enhancing safety and efficacy. To inform the future direction of this field, it is useful to reflect on the scientific and technological advances that have occurred since those early uses. In this review, we explore how dosimetry has evolved over the years and discuss why such initiatives were conceived and the importance of maintaining standards within our practise. Specific milestones and landmark publications are highlighted and a thematic review and significant outcomes during each decade are presented.

Citing Articles

Learning from the past: a century of accuracy, aspirations, and aspersions in brachytherapy.

Melhus C, Simiele S, Aima M, Richardson S Br J Radiol. 2022; 95(1140):20220500.

PMID: 35969474 PMC: 9733622. DOI: 10.1259/bjr.20220500.

References

SNYDER W, Fisher Jr H, Ford M, Warner G . Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. J Nucl Med. 1969; :Suppl 3:7-52. View

Murray I, Chittenden S, Denis-Bacelar A, Hindorf C, Parker C, Chua S . The potential of Ra and F-fluoride imaging to predict bone lesion response to treatment with Ra-dichloride in castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017; 44(11):1832-1844. PMC: 6175045. DOI: 10.1007/s00259-017-3744-y. View

Chiesa C, Sjogreen-Gleisner K, Walrand S, Strigari L, Flux G, Gear J . EANM dosimetry committee series on standard operational procedures: a unified methodology for Tc-MAA pre- and Y peri-therapy dosimetry in liver radioembolization with Y microspheres. EJNMMI Phys. 2021; 8(1):77. PMC: 8589932. DOI: 10.1186/s40658-021-00394-3. View

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P . Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999; 26(11):1439-47. View

Sundlov A, Sjogreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P . Individualised Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017; 44(9):1480-1489. PMC: 5506097. DOI: 10.1007/s00259-017-3678-4. View

Vose J . Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist. 2004; 9(2):160-72. DOI: 10.1634/theoncologist.9-2-160. View

Sjogreen Gleisner K, Chouin N, Minguez Gabina P, Cicone F, Gnesin S, Stokke C . EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022; 49(6):1778-1809. PMC: 9015994. DOI: 10.1007/s00259-022-05727-7. View

Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L . Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005; 46 Suppl 1:99S-106S. View

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

10.

Doai M, Watanabe N, Takahashi T, Taniguchi M, Tonami H, Iwabuchi K . Sensitive immunodetection of radiotoxicity after iodine-131 therapy for thyroid cancer using γ-H2AX foci of DNA damage in lymphocytes. Ann Nucl Med. 2012; 27(3):233-8. DOI: 10.1007/s12149-012-0678-0. View

11.

de Jong M, Bakker W, Krenning E, Breeman W, van der Pluijm M, Bernard B . Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997; 24(4):368-71. DOI: 10.1007/BF00881807. View

12.

Lashford L, Lewis I, Fielding S, Flower M, Meller S, Kemshead J . Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol. 1992; 10(12):1889-96. DOI: 10.1200/JCO.1992.10.12.1889. View

13.

Chiesa C, Strigari L, Pacilio M, Richetta E, Cannata V, Stasi M . Dosimetric optimization of nuclear medicine therapy based on the Council Directive 2013/59/EURATOM and the Italian law N. 101/2020. Position paper and recommendations by the Italian National Associations of Medical Physics (AIFM) and Nuclear.... Phys Med. 2021; 89:317-326. DOI: 10.1016/j.ejmp.2021.07.001. View

14.

Bolch W, Eckerman K, Endo A, Hunt J, Jokisch D, Kim C . ICRP Publication 143: Paediatric Reference Computational Phantoms. Ann ICRP. 2020; 49(1):5-297. DOI: 10.1177/0146645320915031. View

15.

MAYNEORD W, Sinclair W . The dosimetry of artificial radioactive isotopes. Adv Biol Med Phys. 1953; 3:1-63. DOI: 10.1016/b978-1-4831-9926-9.50005-7. View

16.

Niemierko A . Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys. 1997; 24(1):103-10. DOI: 10.1118/1.598063. View

17.

Gregory R, Murray I, Gear J, Leek F, Chittenden S, Fenwick A . Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy. Phys Med Biol. 2019; 64(24):245013. DOI: 10.1088/1361-6560/ab5b6c. View

18.

Gear J, Cox M, Gustafsson J, Sjogreen Gleisner K, Murray I, Glatting G . EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018; 45(13):2456-2474. PMC: 6208822. DOI: 10.1007/s00259-018-4136-7. View

19.

Kwekkeboom D, de Herder W, Kam B, Van Eijck C, Van Essen M, Kooij P . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13):2124-30. DOI: 10.1200/JCO.2007.15.2553. View

20.

Genolla J, Rodriguez T, Minguez P, Lopez-Almaraz R, Llorens V, Echebarria A . Dosimetry-based high-activity therapy with I-metaiodobenzylguanidine (I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma. Eur J Nucl Med Mol Imaging. 2019; 46(7):1567-1575. DOI: 10.1007/s00259-019-04291-x. View